Ixchelsis, Eli Lilly, Pfizer deal

Ixchelsis said in July it acquired rights to IX-01 from Pfizer in exchange for an undisclosed equity

Read the full 178 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE